Trial Profile
Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhinoconjunctivitis with or without controlled bronchial asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2013
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Allergopharma
- 25 Sep 2013 Status changed from recruiting to completed, as reported by the European Clinical Trials Database.
- 19 Nov 2012 New trial record